04:22 AM EDT, 03/17/2025 (MT Newswires) -- Scholar Rock ( SRRK ) said Sunday that data from a phase 3 trial of its investigational therapy apitegromab showed "clinically meaningful" and consistent benefits in motor function in patients with spinal muscular atrophy.

The trial is for patients already receiving survival motor neuron treatments, the company said.

The company said the trial achieved its primary endpoint of significant and clinically meaningful improvement in motor function versus a placebo, as reported in October.

The data is now showing that the study is meeting secondary endpoints that measure consistency in improvements, the company said.

Spinal muscular atrophy is a genetic condition that leads to muscle weakness due to loss of spinal cord motor neurons.